Tracy Jennifer Doyle

Tracy Jennifer Doyle

Auto-generated profile, based on publicly available information

Tracy Jennifer Doyle

Brigham and Women's Hospital Boston Massachusetts

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2020 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Open access
AEAnthony J. Esposito
Anthony J. Esposito
AMAravind A. Menon
Aravind A. Menon
AGAuyon J. Ghosh
Auyon J. Ghosh
RPRachel K. Putman
Rachel K. Putman
LFLaura E. Fredenburgh
Laura E. Fredenburgh
TDTracy J. Doyle
Tracy J. Doyle

17 December 2024 in Arthritis & Rheumatology
Verified
Journal Article
Open access
SFSara Faghihi‐Kashani
Sara Faghihi‐Kashani
AYAkira Yoshida
Akira Yoshida
FBFrancisca Bozan
Francisca Bozan
Giovanni ZanframundoGiovanni Zanframundo
Giovanni Zanframundo
DRDavide Rozza
Davide Rozza
TIthe Classification Criteria for Anti‐Synthetase Syndrome Project participating investigators
the Classification Criteria for Anti‐Synthetase Syndrome Project participating investigators
Objective: Anti‐synthetase syndrome (ASSD) is a rare systemic autoimmune rheumatic disease (SARD) with significant heterogeneity and no shared classification criteria. We aimed to identify clinical and serological features associated with ASSD that may be suitable for inclusion in the data‐driven classification criteria for ASSD.Methods: We used a large, international, multicenter “Classification Criteria for Anti‐synthetase Syndrome” (CLASS) project database, which includes both patients with ASSD and controls with mimicking conditions, namely, SARDs and/or interstitial lung disease (ILD). The local diagnoses of ASSD and controls were confirmed by project team members. We employed univariable logistic regression and multivariable Ridge regression to evaluate clinical and serological features associated with an ASSD diagnosis in a randomly selected subset of the cohort.Results: Our analysis included 948 patients with ASSD and 1,077 controls. Joint, muscle, lung, skin, and cardiac involvement were more prevalent in patients with ASSD than in controls. Specific variables associated with ASSD included arthritis, diffuse myalgia, muscle weakness, muscle enzyme elevation, ILD, mechanic's hands, secondary pulmonary hypertension due to ILD, Raynaud phenomenon, and unexplained fever. In terms of serological variables, Jo‐1 and non–Jo‐1 anti‐synthetase autoantibodies, antinuclear antibodies with cytoplasmic pattern, and anti‐Ro52 autoantibodies were associated with ASSD. In contrast, isolated arthralgia, dysphagia, electromyography/magnetic resonance imaging/muscle biopsy findings suggestive of myopathy, inflammatory rashes, myocarditis, and pulmonary arterial hypertension did not differentiate between patients with ASSD and controls or were inversely associated with ASSD.Conclusion: We identified key clinical and serological variables associated with ASSD, which will help clinicians and offer insights into the development of data‐driven classification criteria for ASSD. image

30 July 2022 in Thorax
Verified
Journal Article
Closed access
PDF file
XWXiaoping Wu
Xiaoping Wu
YJYunju Jeong
Yunju Jeong
SFSergio Poli de Frías
Sergio Poli de Frías
IEImaani Easthausen
Imaani Easthausen
KHKatherine Hoffman
Katherine Hoffman
TDTracy J Doyle
Tracy J Doyle
Although interstitial lung disease (ILD) causes significant morbidity and mortality in rheumatoid arthritis (RA), it is difficult to predict the development or progression of ILD, emphasising the need for improved discovery through minimally invasive diagnostic tests. Aptamer-based proteomic profiling was used to assess 1321 proteins from 159 patients with rheumatoid arthritis with interstitial lung disease (RA-ILD), RA without ILD, idiopathic pulmonary fibrosis and healthy controls. Differential expression and gene set enrichment analyses revealed molecular signatures that are strongly associated with the presence and severity of RA-ILD and provided insight into unexplored pathways of disease. These warrant further study as non-invasive diagnostic tools and future therapeutic targets.

28 September 2020 in Seminars in Arthritis and Rheumatism
Verified
Journal Article
Closed access
SHSicong Huang
Sicong Huang
TDTracy J. Doyle
Tracy J. Doyle
MHMark M. Hammer
Mark M. Hammer
SBSuzanne C. Byrne
Suzanne C. Byrne
WHWeixing Huang
Weixing Huang
JSJeffrey A. Sparks
Jeffrey A. Sparks

7 December 2021 in Rheumatology
Verified
Journal Article
Closed access
PDF file
AEAnthony J Esposito
Anthony J Esposito
JSJeffrey A. Sparks
Jeffrey A. Sparks
RGRitu R Gill
Ritu R Gill
HHHiroto Hatabu
Hiroto Hatabu
ESEric J Schmidlin
Eric J Schmidlin
TDTracy J Doyle
Tracy J Doyle
Objectives: Pulmonary disease is a common extraarticular manifestation of RA associated with increased morbidity and mortality. No current strategies exist for screening this at-risk population for parenchymal lung disease, including emphysema and interstitial lung disease (ILD). Methods: RA patients without a diagnosis of ILD or chronic obstructive pulmonary disease underwent prospective and comprehensive clinical, laboratory, functional and radiological evaluations. High resolution CT (HRCT) scans were scored for preclinical emphysema and preclinical ILD and evaluated for other abnormalities. Results: Pulmonary imaging and/or functional abnormalities were identified in 78 (74%) of 106 subjects; 45% had preclinical parenchymal lung disease. These individuals were older with lower diffusion capacity but had similar smoking histories compared with no disease. Preclinical emphysema (36%), the most commonly detected abnormality, was associated with older age, higher anti-cyclic citrullinated peptide antibody titres and diffusion abnormalities. A significant proportion of preclinical emphysema occurred among never smokers (47%) with a predominantly panlobular pattern. Preclinical ILD (15%) was not associated with clinical, laboratory or functional measures. Conclusion: We identified a high prevalence of undiagnosed preclinical parenchymal lung disease in RA driven primarily by isolated emphysema, suggesting that it may be a prevalent and previously unrecognized pulmonary manifestation of RA, even among never smokers. As clinical, laboratory and functional evaluations did not adequately identify preclinical parenchymal abnormalities, HRCT may be the most effective screening modality currently available for patients with RA.

7 December 2023 in Thorax
Verified
Journal Article
Open access
PDF file
TDTracy J Doyle
Tracy J Doyle
PJPierre-Antoine Juge
Pierre-Antoine Juge
APAnna L Peljto
Anna L Peljto
SLSeoyeon Lee
Seoyeon Lee
AWAvram D Walts
Avram D Walts
JLJoyce S Lee
Joyce S Lee
Shortened telomere lengths (TLs) can be caused by single nucleotide polymorphisms and loss-of-function mutations in telomere-related genes (TRG), as well as ageing and lifestyle factors such as smoking. Our objective was to determine if shortened TL is associated with interstitial lung disease (ILD) in individuals with rheumatoid arthritis (RA). This is the largest study to demonstrate and replicate that shortened peripheral blood leukocytes-TL is associated with ILD in patients with RA compared with RA without ILD in a multinational cohort, and short PBL-TL was associated with baseline disease severity in RA-ILD as measured by forced vital capacity percent predicted.